MetaVia to Present Three Late-Breaking Posters on DA-1726 and Vanoglipel at ADA Sessions
MTVA•MetaVia secured acceptance of three late-breaking abstracts at the American Diabetes Association’s 2026 Scientific Sessions highlighting its obesity candidate DA-1726 and GPR119 agonist vanoglipel. Data from the 16-week Phase 1 Part 3 titration study of DA-1726 will be reported in Q4, with vanoglipel combination preclinical results presented.
1. ADA Abstract Acceptance
MetaVia will feature three late-breaking posters at the American Diabetes Association’s 2026 Scientific Sessions in New Orleans from June 5–8. The presentations include one human obesity cohort for DA-1726 and two preclinical studies on vanoglipel combinations targeting metabolic dysfunction-associated steatohepatitis and type 2 diabetes.
2. DA-1726 Phase 1 Titration Study
DA-1726 is a dual oxyntomodulin analog activating GLP-1 and glucagon receptors to reduce appetite and increase energy expenditure. It is currently in a 16-week Phase 1 Part 3 titration trial to assess higher therapeutic doses with improved tolerability, with topline data due in Q4.
3. Vanoglipel Preclinical Insights
Vanoglipel (DA-1241) is a GPR119 agonist that enhances release of GLP-1, GIP and PYY, improving glucose, lipid profiles and liver inflammation. Two posters will detail synergistic hepatoprotective and weight-loss effects when combined with resmetirom in a MASH mouse model and with metformin in an obese mouse model.
